<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368471</url>
  </required_header>
  <id_info>
    <org_study_id>IMD-07</org_study_id>
    <nct_id>NCT01368471</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of MGuard Stent After a Heart Attack</brief_title>
  <acronym>MASTER</acronym>
  <official_title>MASTER: MGUARD for Acute ST Elevation Reperfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InspireMD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InspireMD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to demonstrate the superiority of the MGuard™ stent over&#xD;
      commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better&#xD;
      myocardial reperfusion in primary angioplasty for the treatment of acute ST-elevation&#xD;
      myocardial infarction (STEMI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution</measure>
    <time_frame>60 to 90 minutes after the last angiogram</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of Thrombolysis In Myocardial Infarction (TIMI) 3 flow at the end of the procedure.</measure>
    <time_frame>60-90 minutes after last angiogram</time_frame>
    <description>The incidence of TIMI 3 flow at the end of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)at discharge, 30 days, 6 months and 12 months post-procedure</measure>
    <time_frame>discharge, 30 days, 6 and 12 months post-procedure</time_frame>
    <description>Major Adverse Cardiac Events (MACE): defined as cardiac death, reinfarction (Q wave and non-Q wave), or repeat ischemia-driven target lesion revascularization (TLR) by percutaneous or surgical methods at hospital discharge, 30 days, 6 months and 1 year post-procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">433</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>MGuard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGuard stent will be deployed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS or DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A regular bare metal stent or drug-eluting stent will be deployed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MGuard</intervention_name>
    <description>MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.</description>
    <arm_group_label>MGuard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control BMS or DES</intervention_name>
    <description>Control BMS or DES</description>
    <arm_group_label>BMS or DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  18 years of age&#xD;
&#xD;
          -  ST-segment elevation (more than 2mm in more than contiguous leads)&#xD;
&#xD;
          -  MI with symptom onset less than 12h&#xD;
&#xD;
          -  The patient is willing to comply with specified follow-up evaluations&#xD;
&#xD;
          -  Signed ICF&#xD;
&#xD;
          -  Single de novo lesion in the target (culprit) vessel&#xD;
&#xD;
          -  Target lesion maximum length is 33 mm (by visual estimation)&#xD;
&#xD;
          -  Reference vessel diameter must be more than 3.0 to less than 4.0 mm by visual&#xD;
             estimation&#xD;
&#xD;
          -  Randomization should occur as soon as Presence of TIMI 2 or 3 before randomization&#xD;
             Exclusion Criteria&#xD;
&#xD;
          -  Pregnant or nursing patients&#xD;
&#xD;
          -  Left Bundle Branch Block (LBBB), paced rhythm, or other Electrocardiogram (ECG)&#xD;
             abnormality&#xD;
&#xD;
          -  Impaired renal function&#xD;
&#xD;
          -  Prior coronary artery bypass graft surgery&#xD;
&#xD;
          -  Bleeding diathesis&#xD;
&#xD;
          -  Contraindication to aspirin&#xD;
&#xD;
          -  cardiopulmonary resuscitation&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  chronic warfarin anticoagulation&#xD;
&#xD;
          -  LVEF less than 20%&#xD;
&#xD;
          -  other medical illness&#xD;
&#xD;
          -  participation in another investigational drug or device study that has not reached its&#xD;
             primary endpoint&#xD;
&#xD;
          -  Left main coronary artery disease with 50% stenosis&#xD;
&#xD;
          -  Ostial target lesion&#xD;
&#xD;
          -  Failure to visualize vessel anatomy distal to the culprit lesion&#xD;
&#xD;
          -  Moderate to heavily calcified target lesion or vessel&#xD;
&#xD;
          -  excessive tortuosity&#xD;
&#xD;
          -  bifurcation with a side branch more than 2.0 mm in diameter&#xD;
&#xD;
          -  A significant (greater than 50%) stenosis proximal or distal to the target lesion is&#xD;
             present that cannot be covered by same single stent&#xD;
&#xD;
          -  Diffuse disease distal to target lesion with impaired runoff&#xD;
&#xD;
          -  Any prior stent proximal to the target lesion, or within 10 mm distal of the target&#xD;
             lesion&#xD;
&#xD;
          -  PCI of another lesion performed within 6 months before the index procedure&#xD;
&#xD;
          -  Target lesion located in a saphenous vein graft&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inst Dante Pazzanese of Cardiology, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dariusz Dudek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Catheterization Laboratories, Krakow, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigmund Silber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center at the Isar Academic Teaching Site of the University of Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University Medical Center The Cardiovascular Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinika Kardiologii Inwazyjnej Uniwersytetu Medycznego w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gilghsin: John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Kardiologii Inwazyjnej</name>
      <address>
        <city>Nowy Targ</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kardiologii Inwazyjnej GVM Carint</name>
      <address>
        <city>Oświęcim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milpark Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

